Vitro hopes for better luck on restructuring’s second outing

Mexican glassmaker's debt restructuring offer – triggered by the company's lossess on derivative contracts in 2008 – is likely to be rejected this month, as the company can afford to offer better terms

  • By Sid Verma
  • 13 Aug 2010
Email a colleague
Request a PDF
Mexican glass maker Vitro SAB’s $1.5bn debt restructuring offer is likely to be rejected by bondholders this month, and investors can get a better deal if they continue to fight, an analyst said this week.

Last Friday (August 6), Vitro’s bondholder committee rejected a restructuring offer, estimated to be worth 44 cents on the dollar. But the company said it would push ahead anyway and solicit the consent of bondholders in general in August. Analysts believe the terms offered will be effectively the same as the plan snubbed by the committee.

This involved replacing outstanding debt with: a $500m eight year bond with a coupon starting at 3% and stepping up by
1% a year; a $350m seven year partial payment in kind (Pik) note with 3% and 4% coupons in the first two years and 8% thereafter; $80m of five year convertible notes that can be automatically swapped into shares; and a cash payment of $75m.

Vitro was caught with an imbalanced hedging position on natural gas contracts in 2008, one of a wave of Mexican companies to lose money on derivatives during the turmoil of that year. The company said it would continue to seek a consensual agreement with creditors, though negotiations have been stalled since September last year.

"The consent solicitation that is to be sent out this month — if it is based on the offer already set out — will probably not be received well by the broader creditor group," said Alexander Monroy, Latin American corporate credit analyst at Barclays Capital.

He believes the company has a better ability to pay than it is claiming in its offer. Vitro is projecting Ebitda of $205m for this fiscal year, but according to Monroy its average normalised Ebitda between 2004 and 2008 was $330m.

"The offer seems to be part of a strategy to retain as much value for shareholders vis-à-vis creditors," he said. "Creditors can probably get a better deal if they continue to fight." Monroy believes Vitro could afford to pay 60-65 cents on the dollar.

  • By Sid Verma
  • 13 Aug 2010

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • 18 Jul 2017
1 Citi 244,235.70 910 8.87%
2 JPMorgan 223,767.95 1021 8.13%
3 Bank of America Merrill Lynch 211,276.97 750 7.68%
4 Barclays 166,062.82 634 6.03%
5 Goldman Sachs 162,877.27 537 5.92%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • 18 Jul 2017
1 HSBC 25,202.67 100 7.14%
2 Deutsche Bank 25,125.19 81 7.12%
3 Bank of America Merrill Lynch 21,836.07 58 6.18%
4 BNP Paribas 18,395.95 105 5.21%
5 Credit Agricole CIB 18,048.72 104 5.11%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • 18 Jul 2017
1 JPMorgan 12,578.87 55 8.17%
2 Citi 11,338.07 71 7.36%
3 UBS 10,682.06 44 6.93%
4 Goldman Sachs 10,419.53 53 6.76%
5 Morgan Stanley 10,194.88 57 6.62%